Valuation: Ind-Swift Laboratories Limited

Market Cap 11.4B 119M 105M 97.59M 89.56M 168M 172M 1.16B 453M 5.64B 447M 437M 19.5B P/E 2024
1.41x
P/E 2025 2.38x
Enterprise Value 7.13B 74.45M 65.42M 61.06M 56.04M 105M 107M 724M 283M 3.53B 280M 273M 12.2B EV / Sales 2024
0.14x
EV / Sales 2025 0.12x
Free-Float
40.72%
Yield 2024 *
-
Yield 2025 -
1 day-5.00%
1 week-6.09%
Current month+10.28%
1 month+11.46%
3 months+61.47%
6 months+106.75%
Current year+154.22%
1 week 217.35
Extreme 217.35
243.75
1 month 197.15
Extreme 197.15
248
Current year 88.5
Extreme 88.5
248
1 year 87
Extreme 87
248
3 years 67.15
Extreme 67.15
248
5 years 51.1
Extreme 51.1
248
10 years 15.25
Extreme 15.25
248
Manager TitleAgeSince
Chief Executive Officer 74 1995-01-03
Chief Executive Officer 43 2011-06-14
Director of Finance/CFO - 2018-09-28
Director TitleAgeSince
Director/Board Member 43 -
Chairman 74 -
Director/Board Member 35 2010-03-22
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%-6.09% - - 214M
+0.67%+1.43%+16.90%+74.77% 49.64B
+1.05%+3.84%+64.12%+113.57% 36.54B
+2.06%+2.92%-6.22%+25.17% 12.22B
+2.14%-1.78%+14.55%+75.28% 11.48B
+1.05%+1.16%+31.33%+131.86% 9.04B
+3.08%+3.94%+50.54%-4.41% 6.94B
+0.17%-0.34%+12.61%+31.76% 6.74B
+3.53%+0.87%+5.47%+183.15% 6.45B
+0.61%-6.24%-32.70%-1.66% 5.42B
Average +0.94%-0.74%+17.40%+69.94% 16.05B
Weighted average by Cap. +1.23%+0.45%+26.65%+80.17%

Financials

2024 2025
Net sales 12.97B 135M 119M 111M 102M 191M 196M 1.32B 515M 6.42B 508M 497M 22.19B 5.62B 58.64M 51.53M 48.1M 44.14M 82.63M 84.67M 570M 223M 2.78B 220M 215M 9.61B
Net income 4.21B 43.95M 38.62M 36.05M 33.08M 61.93M 63.45M 427M 167M 2.08B 165M 161M 7.2B 2.5B 26.15M 22.98M 21.45M 19.68M 36.85M 37.76M 254M 99.46M 1.24B 98.18M 96.05M 4.28B
Net Debt -4.15B -43.36M -38.1M -35.56M -32.64M -61.09M -62.6M -422M -165M -2.06B -163M -159M -7.1B -4.27B -44.53M -39.13M -36.53M -33.52M -62.75M -64.3M -433M -169M -2.11B -167M -164M -7.3B
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,246
Date Price Change Volume
26-07-29 224.20 -5.00% 42,471
26-07-28 ₹236.00 -1.56% 8,880
26-07-27 ₹239.75 +5.62% 24,795
26-07-24 ₹227.00 +0.69% 28,516
26-07-23 ₹225.45 -3.30% 14,386